SAN MARINO, Calif., June 04, 2007 /PRNewswire/ -- (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies Corporation today announced the publication of a historic landmark in medical oncology and a definitive benchmark in the emerging field of cancer gene therapy. The first clinical report of its kind, Le Morte du Tumour -- published in the June issue of the International Journal of Oncology, Vol.30, pp. 1297-1307 -- documents the histologic features of tumor destruction observed in chemo-resistant cancers following intravenous infusions of Rexin-G(TM), the world's first tumor-targeted genetic medicine for cancer therapy. In other words, this paper documents the unprecedented efficacy of targeted gene delivery in the tragic battlefield of metastatic cancer, where all other treatments have historically failed.
Previously, Gordon et al. reported that intravenous infusions of
Rexin-G, a pathotropic nanoparticle bearing a cyto-ablative
construct, induced tumor regression, reduced tumor burden, and
improved survival, while enhancing the overall quality-of-life of
patients with otherwise intractable cancers (2006). In this new
clinical paper, the authors describe the major histopathologic and
radiologic features that are characteristic of solid tumors under
the onslaught of Rexin-G administered as a single therapeutic
agent. To further promote tumor eradication and enhance cancer
survival, the potential of an auxiliary gene transfer strategy was
explored, specifically intended to induce cancer auto-immunization.
This immunization strategy uses Rexin-G in combination with
Reximmune-C(TM) a tumor-targeted expression vector bearing a
granulocyte macrophage colony stimulating factor (GM-CSF) gene. The
intent of this two-step approach is to bring a complement of cells
involved in humoral and cell-mediated immunity in close proximity
to the immunizing tumor antigens in a concerted effort to assist in
tumor eradication and to promote a cancer vaccination in situ.